Oskar Slotboom is a Managing Partner at BioGeneration Ventures (BGV), a venture capital firm specializing in early-stage European life sciences companies. His expertise in commercial strategy and business development is built on previous roles as CCO of Avantium and various leadership positions at Crucell, which became part of Johnson & Johnson.
He holds an MBA from INSEAD and a degree in chemical engineering from the University of Twente. Oskar serves on the boards of several portfolio companies, actively guiding their growth and strategy.
He played a key role in one of Europes most successful biotech startups, Acerta Pharma, a BGV portfolio company acquired by AstraZeneca for up to $7 billion.
Read the full overview →Behavioral traits and communication patterns that shape how this person evaluates opportunities, builds trust, and makes decisions in professional settings.
Dominance, influence, steadiness, and calculativeness scores with guidance on how this person prefers to communicate and decide.
Discover additional public profiles from our index.
Looking for someone else? Search here for anyone.